|1.||Grant, Steven: 19 articles (05/2013 - 05/2002)|
|2.||Dent, Paul: 17 articles (05/2013 - 05/2002)|
|3.||Dai, Yun: 14 articles (05/2013 - 05/2002)|
|4.||Sausville, Edward A: 9 articles (10/2013 - 11/2002)|
|5.||Pei, Xin-Yan: 8 articles (02/2011 - 04/2004)|
|6.||Eastman, Alan: 7 articles (11/2009 - 07/2002)|
|7.||Rahmani, Mohamed: 6 articles (06/2005 - 07/2002)|
|8.||Dancey, Janet: 5 articles (01/2013 - 05/2007)|
|9.||Gandara, David R: 4 articles (04/2012 - 04/2003)|
|10.||Mack, Philip C: 4 articles (04/2012 - 04/2003)|
01/01/2007 - "Thus, by defining the mechanism of cell death on G(2) checkpoint abrogation we show a highly improved strategy for an anticancer treatment by the combined use of UCN-01 with abrogators of the survivin/Aurora B-dependent antiapoptotic pathway that retains the selectivity for p53-defective cancer cells."
12/01/2015 - "The results of plasma profile and tumor regression study demonstrated that E-U-CH NP has continuous release profile of UCN 01 and comprehensive residence time. "
01/01/2007 - "Recent studies have reported that the PKC inhibitor, 7-hydroxystaurosporine, inhibits tumor cell invasion. "
02/01/2006 - "This phase I study was designed to determine the maximal tolerated dose (MTD), recommended phase 2 dose (RPTD), toxicity profile, pharmacokinetics and antitumor activity of T and UCN-01 in patients with refractory solid tumors. "
11/01/2005 - "The present studies determined whether UCN-01 and MEK1/2 inhibitors interacted to cause tumor cell death in vivo. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/2003 - "This combination may have potential clinical applications for breast cancer treatment, by reducing the toxicity of UCN-01."
07/19/2002 - "UCN-01 abrogated S and G(2) arrest in the p53 mutant breast tumor cell line MDA-MB-231 but not in the p53 wild-type breast line, MCF10a. "
01/01/2002 - "UCN-01 (7-hydroxystaurosporine) inhibits the growth of human breast cancer xenografts through disruption of signal transduction."
01/01/2013 - "A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer."
11/01/2005 - "In vitro colony formation studies demonstrated that UCN-01 and the MEK1/2 inhibitor PD184352 interacted to synergistically kill human mammary carcinoma cells (MDA-MB-231, MCF7) with similar combination index values. "
06/01/1996 - "It is concluded that UCN-01 is an effective agent for the inhibition of glioma proliferation in vitro and in vivo and has potential for clinical applicability in the treatment of human gliomas."
04/01/2005 - "UCN-01 inhibits the invasion and migration of human glioma cells. "
06/01/1996 - "A striking inhibition of proliferation was produced by UCN-01 in each of the cell lines, with a median effective concentration of 20 to 100 nM, which correlated with the median in vitro PKC inhibitory concentration of 20 to 60 nM for this agent in the U-87 and SG-388 glioma cell lines. "
04/01/2005 - "Accordingly, UCN-01 can have potential clinical applications for the treatment of human glioma metastasis."
06/01/2002 - "These studies suggest that induction of apoptosis in glioma cells by use of UCN-01 may promote the uptake of tumor antigens by DCs. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/01/2004 - "To test the hypothesis that therapy-induced cell cycle effects would have an impact on the efficacy of a combination of UCN-01 plus ionizing radiation, the cell cycle responses of the non-small cell lung cancer cell lines Calu1 (TP53-null) and A549 (wild-type TP53) to 2 Gy ionizing radiation were correlated with clonogenic survival after irradiation plus UCN-01. "
09/01/1999 - "To determine whether specific genetic abnormalities would modulate the response to UCN-01, a model of human non-small cell lung carcinoma (NSCLC) cell lines with differential abnormalities of p16CDKN2, RB, and p53 was used for these studies. "
12/01/2004 - "Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells."
09/01/1999 - "RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma."
09/01/1999 - "Long-term exposure of human A549 non-small cell lung cancer cells to UCN-01 furnished cells (A549/UCN) with acquired resistance against UCN-01. "
|5.||Hematologic Neoplasms (Hematological Malignancy)
01/01/2001 - "In conclusion, flavopiridol and UCN-01 are cdk modulators that reach biologically active concentrations effective in modulating CDK in vitro, and show encouraging results in early clinical trials in patients with refractory hematopoietic malignancies. "
04/01/2002 - "Drugs showing activity with unique mechanisms of actions are being further developed for treatment of hematopoietic neoplasms, prominent examples being flavopiridol, UCN-01 and depsipeptide among others."
|6.||Staphylococcal Protein A (A, Protein)
|7.||Protein Kinase C
|9.||Protein Kinases (Protein Kinase)
|10.||2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamide
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)